Should you buy Altimmune stock now?
No, the technical signal for Altimmune is currently Strong Sell. Altimmune trades at $2.20 as of Oct 17, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.214 with falling momentum (signal: -0.159); RSI is at 20.1 (oversold), which could point to a potential buying opportunity; the stock is in a short-term downtrend (price below the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Altimmune stock?
There is currently no active analyst price target for Altimmune.
Is Altimmune a dividend stock?
No, Altimmune does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Altimmune stock?
Altimmune is rated as a stock in the risk category Speculative. the annual standard deviation is 69.0%, which classifies the stock as Speculative. In addition, an RSI of 20.1 signals oversold (potential bottom).
Is Altimmune overvalued?
Altimmune has the following valuation ratios: a P/S ratio of 14,494.7, a P/B ratio of 1.3.
Is Altimmune overbought?
No, Altimmune is actually oversold with an RSI of 20.1 (below 30). The technical indicators show: RSI is at 20.1 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, the price is 20.5% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish). IMPORTANT: The stock is oversold in a downtrend. A low RSI in a downtrend is NOT a buy signal – the price can keep falling. Wait for a trend reversal before buying.
When is the next Altimmune earnings report?
Altimmune reports its next earnings on November 5, 2026. The stock currently trades at $2.20. The RSI is at 20.1, so the report can reinforce the current technical trend.
Is Altimmune shorted?
Yes, Altimmune is shorted with 23.7% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Altimmune stock?
Yes, insiders are net buyers of Altimmune – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 0 sales. On a net basis, 44,250 $ worth of shares were bought. Across the last 20 reported transactions, the split is 17 purchases and 3 sales, with a net 285,706 $ sold. Active buyers include Durso Jerome Benedict, GILL JOHN, WEAVER GREGORY L and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Altimmune a good stock?
Based on our total score, Altimmune is rated as a disastrous stock with a total score of 14 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 21/100, Quality: 12/100, Momentum: 9/100. Whether now is the time to buy is a separate question: the technical signal is Strong Sell. Whether Altimmune is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Altimmune stock?
The outlook for Altimmune based on current data: the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Nov 5, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Altimmune stock falling?
Altimmune is falling right now. The technical indicators show: the price is 20.5% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 23.7% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Altimmune go?
There is currently no active analyst price target for Altimmune. The stock has traded between $2.29 and $6.44 over the last 52 weeks. The price is 65.8% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Altimmune fall?
The stock has traded as low as $2.29 over the last 52 weeks — that is 4.1% below the current price of $2.20. The biggest decline (drawdown) in the same period was 64.4% from high to low. Within a year, the price typically swings about ±69.0% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Altimmune do?
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabo... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Altimmune as an investment.
Did Altimmune raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Altimmune. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Altimmune making money or losing money?
We have no current profitability data for Altimmune. See the latest report in the earnings history above.
Can Altimmune go bankrupt?
The bankruptcy risk of Altimmune is rated as low. Altman Z2 (a model for assessing financial distress) is 7.93 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 13% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Altimmune have a lot of debt?
No, Altimmune has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 13%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
